MMP-1 (519 A/G) and TIMP-1 (372 T/C) genes polymorphism in an Egyptian sample of Acne vulgaris patients.
MMP-1
TIMP-1
acne
gene polymorphisms
Journal
Journal of cosmetic dermatology
ISSN: 1473-2165
Titre abrégé: J Cosmet Dermatol
Pays: England
ID NLM: 101130964
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
revised:
08
06
2021
received:
03
12
2020
accepted:
28
06
2021
pubmed:
3
7
2021
medline:
6
4
2022
entrez:
2
7
2021
Statut:
ppublish
Résumé
Different Matrix metalloproteinases (MMPs) family members may be implicated in acne vulgaris development. However, there are no published data about the role of MMP-1 and TIMP-1 gene polymorphisms in acne vulgaris development. To evaluate the association between MMP-1 (519 A/G) and TIMP-1 (372 T/C) gene polymorphisms and the risk of developing acne vulgaris among a sample of Egyptian acne patients. This case-control study included 100 acne vulgaris patients and 120 apparently healthy control subjects. Acne severity was assessed according to Global Acne Grading System (GAGS). MMP-1 (519 A/G) and TIMP-1 (372 T/C) gene polymorphisms were investigated using RFLP-PCR technique. The MMP-1 (519 A/G) AG and GG genotypes and G allele increase the risk of acne vulgaris~2-3 folds. In female patients, TIMP-1 (372 C/T) TT genotype and T allele showed significantly higher frequency in cases compared with the control group (p = 0.004, 0.001 respectively) with a higher risk to develop acne. On the other hand, in male patients, there was insignificant difference between the frequency of alleles in patients and control subjects. TIMP-1 (372C/T) TT genotype has been shown to be significantly detected in the studied female patients associated with the positive family history of the disease, and it increases the risk of back affection, severe acne grade development, and the liability to postacne scar formation. MMP-1 (519 A/G) and TIMP-1 (372 T/C) gene polymorphisms may be related to acne vulgaris development.
Sections du résumé
BACKGROUND
BACKGROUND
Different Matrix metalloproteinases (MMPs) family members may be implicated in acne vulgaris development. However, there are no published data about the role of MMP-1 and TIMP-1 gene polymorphisms in acne vulgaris development.
AIMS
OBJECTIVE
To evaluate the association between MMP-1 (519 A/G) and TIMP-1 (372 T/C) gene polymorphisms and the risk of developing acne vulgaris among a sample of Egyptian acne patients.
PATIENTS/METHODS
METHODS
This case-control study included 100 acne vulgaris patients and 120 apparently healthy control subjects. Acne severity was assessed according to Global Acne Grading System (GAGS). MMP-1 (519 A/G) and TIMP-1 (372 T/C) gene polymorphisms were investigated using RFLP-PCR technique.
RESULTS
RESULTS
The MMP-1 (519 A/G) AG and GG genotypes and G allele increase the risk of acne vulgaris~2-3 folds. In female patients, TIMP-1 (372 C/T) TT genotype and T allele showed significantly higher frequency in cases compared with the control group (p = 0.004, 0.001 respectively) with a higher risk to develop acne. On the other hand, in male patients, there was insignificant difference between the frequency of alleles in patients and control subjects. TIMP-1 (372C/T) TT genotype has been shown to be significantly detected in the studied female patients associated with the positive family history of the disease, and it increases the risk of back affection, severe acne grade development, and the liability to postacne scar formation.
CONCLUSION
CONCLUSIONS
MMP-1 (519 A/G) and TIMP-1 (372 T/C) gene polymorphisms may be related to acne vulgaris development.
Substances chimiques
TIMP1 protein, human
0
Tissue Inhibitor of Metalloproteinase-1
0
MMP1 protein, human
EC 3.4.24.7
Matrix Metalloproteinase 1
EC 3.4.24.7
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1705-1711Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Ibrahim AA, Salem RM, El-Shimi OS, Baghdady SMA, Hussein S. IL1A (-889) gene polymorphism is associated with the effect of diet as a risk factor in Acne Vulgaris. J Cosmet Dermatol. 2019;18(1):333-336.
Raeeszadeh-Sarmazdeh M, Do LD, Hritz BG. Metalloproteinases and their inhibitors: Potential for the development of new therapeutics. Cells. 2020;9(5):1313.
Bourboulia D, Stetler-Stevenson WG. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion. Semin Cancer Biol. 2010;20(3):161-168.
Gao R, Yu H, Zhao Q, Wang S, Bai B. Role of MMP-2(-1306 C/T) and TIMP-2(-418G/C) polymorphism in Chinese Han patients with Acne vulgaris. Biomed Res Int. 2019;2019:2364581.
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19-25.
Doshi A, Zaheer A, Stiller MJ. A comparison of current acne grading systems and proposal of a novel system. Int J Dermatol. 1997;36(6):416-418.
Baroneza JE, Godoy-Santos A, Ferreira Massa B, Boçon de Araujo Munhoz F, Diniz Fernandes T, Leme Godoy dos Santos MC. Leme Godoy dos Santos MC. MMP-1 promoter genotype and haplotype association with posterior tibial tendinopathy. Gene. 2014;547(2):334-337.
Padala C, Tupurani MA, Puranam K, et al. Synergistic effect of collagenase-1 (MMP1), stromelysin-1 (MMP3) and gelatinase-B (MMP9) gene polymorphisms in breast cancer. PLoS One. 2017;12(9):e0184448.
Hashimoto T, Uchida K, Okayama N, et al. Association of matrix metalloproteinase (MMP)-1 promoter polymorphism with head and neck squamous cell carcinoma. Cancer Lett. 2004;211(1):19-24.
Nishizawa R, Nagata M, Noman AA, et al. The 2G allele of promoter region of matrix metalloproteinase-1 as an essential pre-condition for the early onset of oral squamous cell carcinoma. BMC Cancer. 2007;7:187.
Mazzarella N, Femiano F, Gombos F, De Rosa A, Giuliano M. Matrix metalloproteinase gene expression in oral lichen planus: erosive vs. reticular forms. J Eur Acad Dermatol Venereol. 2006;20(8):953-957.
Wang LE, Huang YJ, Yin M, et al. Promoter polymorphisms in matrix metallopeptidase 1 and risk of cutaneous melanoma. Eur J Cancer. 2011;47(1):107-115.
Garza-Gómez J, Cerda-Flores RM, Gómez-Flores M, et al. An investigation into the MMP1 gene promoter region polymorphism-1607 2G with recessive dystrophic epidermolysis bullosa disease severity in Northeastern Mexican patients. Int J Dermatol. 2014;53(8):985-990.
Gowri BV, Chandravathi PL, Sindhu PS, Naidu KS. Correlation of skin changes with hormonal changes in polycystic ovarian syndrome: A cross-sectional study clinical study. Indian J Dermatol. 2015;60(4):419.
Walch K, Nagele F, Zeillinger R, Vytiska-Binstorfer E, Huber JC, Hefler LA. A polymorphism in the matrix metalloproteinase-1 gene promoter is associated with the presence of polycystic ovary syndrome in Caucasian women. Fertil Steril. 2005;83(5):1565-1567.
Nho YK, Ha E, Yu KI, et al. Matrix metalloproteinase-1 promoter is associated with body mass index in Korean population with aged greater or equal to 50 years. Clin Chim Acta. 2008;396(1-2):14-17.
Checa M, Ruiz V, Montaño M, Velázquez-Cruz R, Selman M, Pardo A. MMP-1 polymorphisms and the risk of idiopathic pulmonary fibrosis. Hum Genet. 2008;124(5):465-472.
Meng C, Yin X, Liu J, Tang K, Tang H, Liao J. TIMP-1 is a novel serum biomarker for the diagnosis of colorectal cancer: A meta-analysis. PLoS One. 2018;13(11):e0207039.
Lorente L, Martín M, Plasencia F, et al. The 372 T/C genetic polymorphism of TIMP-1 is associated with serum levels of TIMP-1 and survival in patients with severe sepsis. Crit Care. 2013;17(3):R94.
Indelicato M, Chiarenza V, Libra M, et al. Analysis of TIMP-1 gene polymorphisms in Italian Sclerodermic patients. J Clin Lab Anal. 2006;20(5):173-176.
Behnes M, Bertsch T, Hoffmann U. TIMP-1 gene polymorphism: are genetics able to predict outcome of septic patients? Crit Care. 2013;17(4):170.
Kumar M, Bhadoria DP, Dutta K, et al. Combinatorial effect of TIMP-1 and α1AT gene polymorphisms on development of chronic obstructive pulmonary disease. Clin Biochem. 2011;44(13):1067-1073.
Markiewicz L, Majsterek I, Przybylowska K, et al. Gene polymorphisms of the MMP1, MMP9, MMP12, IL-1β and TIMP1 and the risk of primary open-angle glaucoma. Acta Ophthalmol. 2013;91(7):e516-e523.
Bhate K, Williams HC. Epidemiology of acne vulgaris. Br J Dermatol. 2013;168(3):474-485.
Chuah SY, Goh CL. The impact of post-acne scars on the quality of life among young adults in Singapore. J Cutan Aesthet Surg. 2015;8(3):153-158.
Soliman YS, Horowitz R, Hashim PW, Nia JK, Farberg AS, Goldenberg G. Update on acne scar treatment. Cutis. 2018;102(1):21-25, 47-48.
Manicone AM, McGuire JK. Matrix metalloproteinases as modulators of inflammation. Semin Cell Dev Biol. 2008;19(1):34-41.
Ries C. Cytokine functions of TIMP-1. Cell Mol Life Sci. 2014;71(4):659-672.
Van Roy M, Wielockx B, Baker A, Libert C. The use of tissue inhibitors of matrix metalloproteinases to increase the efficacy of a tumor necrosis factor/interferon gamma antitumor therapy. Cancer Gene Ther. 2007;14(4):372-379.
Al-Harbi M. Concerns and awareness of acne patients about isotretinoin in Qassim region of Saudi Arabia. Int J Health Sci (Qassim). 2010;4(1):47-51.
Kara Polat A, Akin Belli A, Ergun EZ, et al. Knowledge levels and concerns about oral isotretinoin treatment in the parents of adolescent acne patients. Dermatol Ther. 2020;33(4):e13669.
Dave DD, Abdelmaksoud A. Low dose isotretinoin for pigmented post-varicella scars. Dermatol Ther. 2019;32(1):e12768.
Hayashi N, Miyachi Y, Kawashima M. Prevalence of scars and "mini-scars", and their impact on quality of life in Japanese patients with acne. J Dermatol. 2015;42(7):690-696.
El-Taweel AA, Salem RM, El-Shimi OS. Predictive value of serum markers for postacne scarring. J Cosmet Dermatol. 2018;17(3):491-494.